Media Relation

 NurrOn, HanAllBiopharma and Daewoong Pharmaceutical initiated first-in-human Phase I clinical study of ATH-399A. 

HanAllBiopharma, DaewoongPharmaceutical and NurrOnPharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 – WSJ

HanAllBiopharma, DaewoongPharmaceutical and NurrOnPharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 – Bloomberg

HanAllBiopharma, DaewoongPharmaceutical and NurrOnPharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192 (yahoo.com)

NurrOn entered into co-development agreement with HanAll Biopharma and Daewoong Pharmaceuticals to develop ATH-399A for Parkinson’s disease.

https://www.prnewswire.com/news-releases/hanall-biopharma-and-daewoong-pharmaceutical-enter-into-co-development-agreement-with-nurron-pharmaceuticals-to-develop-therapy-for-parkinsons-disease-301834508.html

NurrOn received the award of the translational pipeline program 2022 for a Phase I trial of ATH-399A from Michael J. Fox Foundation.

https://www.michaeljfox.org/grant/development-nurr1-activator-novel-therapeutic-parkinsons-disease